FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
Subscribe To Our Newsletter & Stay Updated